Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06966804

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Efficacy of Alpha Blockers (Terazosin vs Tamsulosin) in Reducing Ureteral Stent Related Symptoms - An Open-label, Randomized Controlled Trial

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Penang Hospital, Malaysia · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications. Main objective: • To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms. Secondary objectives: * To compare painkiller use among the groups. * To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ). * To assess differences in side effects. After stent placement, subjects will be randomly assigned to one of three groups: 1. Terazosin (alpha-blocker) for 14 days 2. Tamsulosin (alpha-blocker) for 14 days 3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin groups will receive respective study medications to complete 14 days course of treatment. Follow-Up: * Day 7: A phone call will check medication use and any side effects. * Day 15: Clinic visit for stent removal (standard practice). Subjects will complete the USSQ questionnaire, and medication compliance will be reviewed. End of study: Final phone call to check for any additional side effects.

Conditions

Interventions

TypeNameDescription
DRUGTerazosinSubject will complete 14-day course of Terazosin
DRUGTamsulosinSubject will complete 14-day course of Tamsulosin

Timeline

Start date
2025-06-01
Primary completion
2026-05-31
Completion
2026-05-31
First posted
2025-05-13
Last updated
2025-09-05

Locations

2 sites across 1 country: Malaysia

Source: ClinicalTrials.gov record NCT06966804. Inclusion in this directory is not an endorsement.